Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neuromuscular disease: CRISPR/Cas9 gene-editing platform corrects mutations associated with Duchenne muscular dystrophy.

Nature reviews. Neurology - 1 Apr 2015

Wood Heather

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR-Cas Systems
Share to Dystrophin
Share to Genome
Share to Muscular Dystrophy, Duchenne

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Source

Identifiers

PMID: 25752950
DOI: 10.1038/nrneurol.2015.37

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neuromuscular disease: CRISPR/Cas9 gene-editing platform corrects mutations associated with Duchenne muscular dystrophy.PMID 25752950Read ↗

Making gene editing a therapeutic realitySemantic proximity Read ↗

Correction of muscular dystrophies by CRISPR gene editing.Semantic proximity Read ↗

CRISPR Therapeutics for Duchenne Muscular DystrophySemantic proximity Read ↗

CRISPR technologies for the treatment of Duchenne muscular dystrophy.Semantic proximity Read ↗

Neuromuscular disease: Genome editing shows promise in an in vivo model of Duchenne muscular dystrophy.Semantic proximity Read ↗

Genome Editing of Monogenic Neuromuscular DiseasesSemantic proximity Read ↗

Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications.Semantic proximity Read ↗

Methods of CRISPR/Cas9 Exon Skipping for Duchenne Muscular DystrophySemantic proximity Read ↗

Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging TherapiesSemantic proximity Read ↗

Clinical trials and promising preclinical applications of CRISPR/Cas gene editingSemantic proximity Read ↗

CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human DiseasesSemantic proximity Read ↗

CRISPR/Cas correction of muscular dystrophies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.